Grifols is expected to report Q2 2026 revenue of $2.06 billion and EPS of $0.27, with the stock currently trading at $9.45 against an average analyst price target of $14.20. The primary focus for investors during this earnings call is the company's trajectory for Free Cash Flow (FCF) generation and the status of ongoing deleveraging efforts.
Market sentiment remains sensitive to corporate governance developments and the potential take-private bid led by Brookfield and the Grifols family. Success in margin expansion within the plasma segment and the integration of Biotest assets remain critical factors for the company to meet its ambitious full-year 2026 financial targets.